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Background: The « reversed treatment» approach inverts the treatment sequence of 
advanced synchronous colorectal liver metastases - i.e. the liver metastasis is 
treated first, followed by resection of the primary tumor. Chemotherapy is performed 
before and after liver surgery. We recently started to use a reversed treatment 
approach in selected patients. The aim of this study is to critically assess this new 
treatment modality. 
Methods: Nine patients (7 male, 2 female, mean age 62 years) benefited from this 
new treatment between November 2008 and May 2010. The data were collected 
retrospectively. 
Results: All patients responded to the neoadjuvant chemotherapy. The median 
number of liver metastases was 6 (range 1 - 22). The median size of the largest liver 
metastases was 4.3 cm (range 2.6 – 13 cm). Three patients had portal vein 
embolization prior to liver surgery. Two patients could not complete the treatment. 
One had to undergo emergency surgery for occluding colonic tumor. The second one 
showed liver recurrence before starting the adjuvant chemotherapy. The seven 
patients who completed the treatment are still alive after a median time of 27 months 
(range 17 – 37 months). Seven of them had recurrence (1 rectal, 6 liver). The median 
disease-free survival was 9 months (range 0 – 17 months). 
Conclusion: Based on our preliminary experiences, the reversed strategy shows 
encouraging results for the treatment of advanced synchronous colorectal liver 
metastases in well selected patients. The treatment was generally well tolerated and 
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Colorectal cancer means an important medical issue. In the United States, 
more than 140'000 patients have been diagnosed in 2010, which represents 10% of 
all cancer cases.1 In Europe, it accounts for 13% of all cancer cases, with more than 
400'000 new cases in 2008.2 In those years, more than 50'000 patients died from 
their colorectal tumors in the US, and approximately 200'000 in Europe.1,2,3 About 
50% of colorectal cancer patients will develop liver metastases during the course of 
their disease. Colorectal liver metastases (CRLM) may occur simultaneously with the 
primary tumor (synchronous CRLM) or after resection of the primary tumor as 
delayed progression of the disease (metachronous CRLM).  
 
The traditional treatment of patients with synchronous CRLM is to remove the 
primary tumor first to avoid local complications, e.g. obstruction, bleeding, and pain. 
Resection of liver metastases is performed as a second intervention several weeks 
later, after full recovery of patients and chemotherapy. Adjuvant chemotherapy aims 
to reduce local recurrence of the primary tumor as well as to stabilize or even 
decrease the size and number of CRLM. In addition, non-responders to 
chemotherapy who reveal a tumor progression can be identified, and unnecessary 
surgery can be avoided.4 Simultaneous resection of the primary tumor combined with 
major liver surgery has been abandoned due to an increased postoperative 
morbidity.5 Moreover; no current studies could define a better long-term survival after 
single versus staged resections. 
This aforementioned treatment has been increasingly challenged during recent 
years since it is known that long-term survival in case of simultaneous CRLM is 
rather determined by the liver metastases than the primary tumor. The advent of new 
anticancer drugs and advances in liver surgery are the main factors that initiated the 
development of new treatment strategies. Irinotecan, capecitabine and oxaliplatin 
reveal increased tumor response rates up to 40-50% compared to <25% that could 




be achieved by using older treatment regimens with 5-fluorouracil (5-FU) and 
leucovorin (LV). New combinations of these five drugs are able to further raise the 
response rate to 70%. Most recently, monoclonal antibodies against VEGF (vascular 
endothelial growth factor), e.g. bevacizumab, and EGFR (epidermal growth factor 
receptor, e.g. cetuximab have been introduced. Response rates of nearly 100% have 
been shown.6,7 Better understanding of liver function, i.e. liver regeneration as well as 
improved operation techniques, decreased the morbidity and mortality rates of major 
liver resections. The surgical armamentarium has also been added by modern 
interventional radiology. Thermal tumor ablation by using radiofrequency, and 
induction of liver hypertrophy by portal vein embolization are of particular value.3 For 
well selected cases, metastasis resection can be done by a laparoscopic approach.7  
 
Since primary and metastatic tumor growth can be effectively controlled, the 
so-called “reversed treatment” of advanced synchronous colorectal liver metastases 
or “liver-first approach” has been proposed as novel therapeutic approach. As CRLM 
define the long-term outcome (i.e. survival), it seems sensible to target them first. 
This approach allows control of the metastases at the same time as the primary, 
avoiding their progression while treating the colorectal tumor. The aim of this new 
strategy is to offer to patients with stage IV colorectal cancer a treatment of the 
primary and the metastases with curative intent to increase survival.4 Prior to surgical 
resection of the liver metastasis, patients receive neoadjuvant chemotherapy with the 
aim to stop further tumor growth or even downsizing liver metastasis. After re-
staging, resection of liver metastasis is then performed. Finally, the primary tumor is 
resected, often requiring a second intervention. It remains optional, whether 
chemotherapy is continued until the primary tumor will be removed. Actually, only few 
patients have benefited from this novel approach. Mentha et al. studied the 
effectiveness of this treatment on 30 patients. The survival rates for patients who 
completed the treatment at 1, 2, 3, 4 and 5 years were 100%, 89%, 60%, 44% and 
31%, respectively. The median survival was 44 months. In comparison, the 5-year 
survival rates of patients undergoing the traditional treatment range between 25% 
and 58%.8  





The Department of Visceral Surgery, CHUV, recently started to use the 
reversed treatment in selected patients. The aim of this study is to critically assess 






















Patients and Methods 
 
There were nine patients who benefited from a reversed treatment for 
advanced colorectal liver metastases with curative intent from November 2008 to 
May 2010. All patients presented a colonic or rectal primary tumor and synchronous 
liver metastases without further metastases at other sites. Chemotherapy regimens 
were chosen by the patient’s oncologists according to their characteristics. 
Chemotherapy regimens were documented in the CHUV database if the patient was 
followed at the Department of Medical Oncology of the hospital. If not, the external 
oncologist was contacted to get the treatment protocol. Radiological statements were 
consulted to prove tumor response to chemotherapy.  
Patients were identified from prospective databases of the Department of 
Visceral Surgery. Medical charts, radiological and pathological reports were carefully 
reviewed to extract patients’ data and outcome parameters. Data were 
retrospectively documented on a separate data sheet developed for each patient; 
and entered into an electronical database. 
The study was approved by our internal Institutional Review Board. All patients 
signed informed consent prior to liver and colorectal surgery, respectively. 
All patients underwent major liver surgery at the CHUV, whereas colorectal 
surgery was done in part at the CHUV and for some patients in other hospitals. Some 
documents were to be asked to the patients’ surgeon. Surgical treatment of liver 
recurrence was done at the CHUV, while colorectal recurrence was operated 
elsewhere.  
Postoperative complications were graded according to their severity. A 
validated therapy-orientated complication score was used.9 Complications were 
reported as number of complications, whereby more than one complication per 
patient was possible. 




Overall survival was calculated from first diagnose to death of the patient. 
Disease-free survival was calculated as time interval between colorectal surgery and 



















There were nine patients (7 men and 2 women) with a median age of 64 years 
(range 46 to 77 years), who were treated with the liver first approach. None of them 
had severe co-morbidities. Patients underwent colonoscopy and imaging control (CT-
Scan and Ultrasonography of the liver or/and MRI or/and PET-CT) (Table 1). 
They presented colorectal cancer and synchronous liver metastases with no 
other metastatic site. Five patients presented adenocarcinoma of the colon, while two 
patients had a rectal primary. The two others presented both colon and rectum 
tumor. The median number of liver metastases was six (range 1 – 22). The median 
size of the largest liver metastasis was 4.3 cm (range 2.6 – 13 cm).  
 
Chemotherapy 
All patients were treated with neo-adjuvant chemotherapy prior to surgery. 
They received 2 to 10 cycles of combination therapy. Three patients were given 8 to 
10 cycles of OCFL combination – i.e. oxaliplatin at days 1 and 15, irinotecan (CPT-
11) at days 8 and 22, 5-fluorouracil (5-FU) and leucovorin at days 1, 8, 15 and 22. 
Three patients received 2 to 3,5 cycles of the OCFL-BC regimen – i.e. oxaliplatin at 
days 1 and 15, CPT-11 at days 8 and 22, 5-FU at days 1, 8, 15 and 22, leucovorin at 
days 1, 8, 15 and 22 with a weekly infusion of bevacizumab and cetuximab at days 1 
and 15. Two patients received 5 to 6 cycles of FOLFOX/Avastin® – i.e. oxaliplatin at 
day 1, 5-FU as a bolus at day 1 and 2, 5-FU as a continuous perfusion for 24 hours 
at day 1 and 2, and bevacizumab at day 3. The last patient was given a combination 
therapy with 6 cycles of oxaliplatin and capecitabine.  
 
Tumor response to chemotherapy was assessed after 2 to 6 cycles of 
treatment with imaging control, i.e. CT-Scan, MRI or PET-CT, whereby all patients 
presented radiological shrinkage of both, the metastases and the primary tumor. 




(Figure 1). One patient with an occluding sigmoidal tumor that had to be stented, 
expulsed the stent as the tumor decreased and could restore a normal transit without 
abdominal pain. 
 










 C) D) 
Figure 1. preoperative CT-Scan of one patient with reverse treatment approach. A) and B) show the 
initial CT-scan with a big liver metastasis. C) and D) show the same metastasis after 2 months of 
chemotherapy with the OCFL regimen.  
 
Some complications related to chemotherapy were encountered, but treatment 
was completed in all patients.  Hematotoxicity occurred in three patients but only one 
developed febrile agranulocytosis and pneumonia. Four patients suffered from 
mucositis (grade III). Two patients developed a grade I neuropathy on oxaliplatin 
treatment. Two patients had a mild allergic reaction to oxaliplatin. One patient had 
recurrent epistaxis. Toxidermitis was encountered in three patients. Five patients 




suffered from severe fatigue. One patient developed acute renal failure caused by 




All patients benefited from liver surgery with curative intent, with a median time 
interval after the last chemotherapy of one month (range 1 – 5 months). Three 
patients underwent portal vein embolization (PVE) prior to liver surgery to increase 
the remnant liver volume. The median time interval between PVE and liver surgery 
was one month (range 1 – 5 months). Liver surgery was based on CT or MRI findings 
and on intraoperative ultrasonography. Of note, imaging studies that have been 
performed prior to neoadjuvant chemotherapy were mainly used since metastasis 
localization after treatment was difficult.  
 
As seen in Table 2, all patients underwent major liver surgery. Meticulous 
inspection of the abdominal cavity was always performed to exclude peritoneal 
carcinomatosis, which was not found in any patient. One patient received six RBC 
(red blood cells) and three FFP (fresh frozen plasma) because of major 
intraoperative bleeding. All other patient had only minor blood loss. There were no 
other intraoperative complications. 
 
Histological examination of the resected masses showed a median viable cell 
percentage of 10% (range 1 – 100%). The best histological response to 
chemotherapy, with 1% remaining viable cells, was obtained with the OCFL-BC 
regimen. The resection was R0 for seven patients and R1 for the two remaining 
patients.  
 




Postoperatively, several patients had surgical or/and medical complications. A 
first patient presented with an intraabdominal abscess that required a laparotomy to 
drain the abscess, and the abdomen had to be left open. A further operation was 
needed to close the laparostoma and to introduce a Vacuum Assisted Closure (VAC) 
therapy. A second patient presented a bilioma, due to stenosis of the left hepatic bile 
duct. He underwent left hepatectomy, which was complicated by an abscess of the 
abdominal wall. Conservative treatment with rinsing and gauze plugging was 
successful to get complete wound healing. The same patient presented a 
pneumothorax and pleural effusion, which had to be drained. A third patient 
presented a bilioma with Staphilococcus epidermidis infection that was drained by 
CT-scan control. This patient received antibiotic therapy with Co-Amoxicillin® for 10 
days, and developed also a delirium. A fourth patient presented two consecutive 
bacteriemias, one with Klebsiella pneumoniae and one with multi-resistant 
Staphilococcus epidermidis (MRSE). Therefore, the patient received antibiotic 
treatment with Ciproxine® and Vancomycine® for 14 days. Another patient presented 
a seroma after discharge but did not consult for it. There was no intraoperative or 
postoperative death.  
Median hospital stay for liver surgery and complications was 15 days (range 8 
– 53 days). (Table 3). 
 















Postoperatively, 2 to 8 cycles of chemotherapy were given to complete the 
oncological treatment. Two patients did not get complementary chemotherapy due to 
prolonged malnutrition. Two patients received 2 to 8 cycles of FOLFOX regimen, one 
had 12 cycles of FOLFOX-4/ bevacizumab and bevacizumab alone for 10 months, 
two had 2 cycles of OCFL-BC, one had a therapy with capecitabine alone and one 
received capecitabine alone followed by 2 cycles of FOLFOX.  
 
Additional pelvic radiotherapy was given to two patients with rectal primary 
tumors. The first patient received five times 25 Gy (5x5 Gy) and the second one 
received 50 Gy (25x2 Gy).  
 
Colorectal surgery 
With a median time interval of two months (range 1 – 5 months) after liver 
surgery, all patients underwent surgical resection of the primary tumor. Two patients 
underwent left hemicolectomy, one had enlarged right hemicolectomy associated 
with metastasectomies of the liver, closure of ileostomy and draining of an abdominal 
abscess, two had low anterior resection, one had low anterior resection with 
sigmoidectomy, one had sigmoidectomy, and one had proctectomy. The last patient 
underwent an emergency right hemicolectomy since he presented subileus caused 
by an occluding colonic tumor. 
 
Postoperatively, five patients presented complications. One presented a 
subileus, while another patient developed a partial hepatic failure. A third patient 
presented a bacteriemia with gram negative germs, which needed a treatment with 
antibiotics and developed an acute coronary syndrome. A patient benefited from 
metastasectomies at the same time as the colorectal surgery and developed 
perihepatic fluid collections, which had to be drained under CT-Scan control twice. 




The fifth patient developed a fibrino-biliary peritonitis caused by a small bowel 
perforation. He underwent emergency laparotomy with a segmental ileum resection 
of 10 cm. There was no intraoperative or postoperative death. Median hospital stay 
was 11 days (range 6 – 33 days).  
 
Length of hospital stay 
Median overall hospital stay in this study was 38 days (range 14 - 63 days), 
with a median of 15 days (range 8 – 53 days) for liver resection and a median of 11 
days (range 6 – 33 days) for colorectal tumor excision. Length of hospital stay was 
mostly influenced by postoperative complications.  
 
Recurrence 
Recurrence of tumor was encountered in seven patients after a median time 
interval of 7 months (range 0 – 17 months) after colorectal surgery. Six patients had 
recurrence in the liver, while the seventh one had new polyps in the caecum and 
ascending colon. The patient with polyp recurrences was treated with polyp excision. 
Since he presented several recurrences, a research for DNA mutations was made 
and showed mutations of the DNA mismatch repair genes (hMLH-1, hMSH-2, hMSH-
6, hPMS-2). Hence, he was found to have microsatellite instability. 
For the six patients with hepatic recurrence, different treatment regimens were 
used. All patients got chemotherapy, five of them with curative intent. Two patients 
were additionally treated with RFA combined with hepatic resection. One patient had 
stereotaxical radiotherapy followed by RFA and one had liver resection only. One 
patient died with disease progression and another was transferred in a palliative 
approach by progressive disease under treatment. Three patients with hepatic 
relapse were in May 2011 alive without evidence of new liver metastases.  
 





The last follow-up of patients was made in May 2011. The patient’s 
oncologists were consulted if no recent document was found in the CHUV database. 
Two patients died, both at 9 months after colorectal surgery, one from upper and 
lower gastrointestinal bleeding, the other from denutrition in a context of global drop 
in general health. Overall survival for those two patients was respectively 17 and 15 
months. Median follow-up was 25 months (range 15 – 37 months). At this time, 
seven from nine patients are still alive after a median period of 27 months (range 17 
– 37 months). The median disease-free survival was 9 months (range 0 – 17 




















In this study, we evaluated our first results of the reversed treatment of 
synchronous colorectal liver metastases, starting by chemotherapy, undergoing liver 
resection then and processing colorectal surgery at last. Several arguments support 
this reversed treatment sequence. 
First, new chemotherapeutics combinations, including agents such as 
cetuximab (Erbitux®, anti-EGFR monoclonal antibody) and bevacizumab (Avastin®, 
anti-Angiogenesis monoclonal antibody), show a response rate up to 70%.10, 11 This 
encourages to start with medication targeting both liver metastases and primary 
colorectal tumor as a first step in the treatment sequence. Theoretically, delayed 
surgery could lead to disease progression of so far resectable liver metastases, thus 
turning them into non-resectable lesions with bad prognosis. In this study, this 
problem was not encountered, and all patients underwent liver resection. This finding 
is in accordance to the current evidence in the literature that covered by systemic 
treatment, surgery can be safely delayed.12  
New chemotherapy agents have more specific targets and are therefore 
generally better tolerated.10 In this study, several patients encountered drug-related 
complications, sometimes requiring to postpone the treatment, but chemotherapy 
was globally well tolerated and all subjects could benefit from a complete treatment. 
Only one patient had to interrupt the treatment because of an anaphylactic reaction. 
After a switch in the regimen, he could complete chemotherapeutic treatment without 
further severe complication.   
Response to chemotherapy is a prognostic factor for survival. Patients with 
disease progression under chemotherapy show higher recurrence rates and lower 
survival rates than those with controlled or regressive disease.13,14,15 Identifying 
patients with responsive disease and those with progressive disease under 
chemotherapy is then crucial. Thereby, the latter patients group with its poor 




prognosis can avoid undergoing unnecessary major surgery, but benefit from a 
palliative approach.   
Patients with initially unresectable liver metastases can benefit from a 
downstaging of the metastases, and will become eligible for a curative approach. 
Symptoms associated to the primary tumor can also be diminished trough systemic 
treatment since downsizing of the primary tumor will relieve luminal obstruction and 
compression syndromes. E.g., one patient in our series presented occlusion of the 
sigmoid colon which had to be stented. During neoadjuvant chemotherapy, luminal 
obstruction completely disappeared, and he spontaneously expulsed the stent. 
Resection of liver metastasis prior to colorectal surgery avoids delayed hepatic 
tumor excision in case of complications after colorectal surgery, as it would happen in 
the standard treatment sequence. Neoadjuvant chemotherapy was somewhat 
controversial due to the potential drug-induced liver injury. Chemotherapy-associated 
parenchymal damage include: vascular modifications (sinusoidal dilatation and 
sinusoidal obstruction syndrome) and chemotherapy-associated steatohepatitis 
(CASH).16 In our study, histological examination of the resected liver specimens 
revealed two patients with sinusoidal dilatation but no sinusoidal obstruction 
syndrome, and six patients with minor CASH. None of them developed clinically 
relevant liver dysfunction.  
In case of rectal primary tumor, the reversed strategy allows to perform 
preoperative radiotherapy of the rectum before excision of the primary tumor. 
Thereby, it avoids postponing radiotherapy if complications of rectum surgery are 
encountered. Preoperative rectal radiotherapy has shown better results than 
postoperative radiotherapy. In fact, preoperative radiotherapy is associated with 
reduced toxicity, less local relapse, and improvement of disease-free survival.17,18,19 
In this study, two patients had preoperative radiotherapy of the rectum that was well 
tolerated. 
In this preliminary experience, seven out of nine patients could undergo the 
whole treatment. Those seven patients are still alive after a median period of 27 
months. Two of them did not show recurrence of disease yet. Among the four 




patients with liver recurrence who benefited from a treatment of the relapse, three are 
alive with no evidence of further liver metastases. The median disease-free survival 
was 9 months. This shows that even with an aggressive treatment, synchronous 
CRLM still remain a complex disease which needs a multidisciplinary approach. 
Thanks to the new advances in surgical techniques, oncological treatments and 
radiofrequency, we are able nowadays to offer to some patients with stage IV 
colorectal cancer a curative approach. Nevertheless, in a greater part of them, all 
























Due to the small number of patients included in this study, no definitive 
conclusion can be made on this basis. However, it seems that this reversed strategy 
is a valuable alternative to classic treatment for stage IV colorectal cancer with liver 
synchronous metastases in well selected patients. Results are encouraging but to 
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